Compound class:
Synthetic organic
Comment: The structure for davelizomib was obtained from proposed INN list 129 (August 2023) where it is described as a proteasome inhibitor and antineoplastic agent. It is example I-1 in patent JP2021531302A. This patent encompasses use of claimed compounds for the treatment of multiple myeloma, and identifies its potential in MM that is resistant to treatment with the existing proteasome inhibitor bortezomib.
|
|
Bioactivity Comments |
Davelizomib (I-1) inhibits proliferation of MM cells with an IC50 of 13 nM in vitro [1]. |